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Open accAutoimmunity in primary biliary cirrhosis: An alternative view
at initiation and function of anti-mitochondrial autoantibodiese Editor:
imary biliary cirrhosis remains a fascinating ﬁeld of
ch, and its possible causes have been intensively
d in the past years. Selmi and colleagues [1] pro-
n their review an update on recent developments
C, and based on their own contributions they
in that an environmental insult intervening on a
ic susceptible background precipitates PBC
gh molecular mimicry. However, in recent years
ideas and models have been developed that may
nge the current paradigm of autoimmunity in gen-
nd justify another view of the initiation of PBC.
artz and Ziv [2], for instance, present the concept
munity to self as a maintenance mechanism to pro-
he integrity of tissue function. Following Matzin-
‘‘danger model” [3], autoimmunity evoked in
nse to a danger signal is a by-product of a neces-
mmune response and as such it can be useful, neu-
r harmful.
sed on these sound immunological ﬁndings, the
uction of the model of ‘‘balanced autoimmune
illance activity” may help to explain some ‘‘incon-
nt truths” [4] in PBC. Protective and organ-speciﬁc
ntibodies may be involved in its pathogenesis. An
rtant argument that AMA ﬁt into this concept is
ct that there is a common evolutionary origin of
hondria. Because mitochondria are of endosymbi-
rigin their proteins represent a transition from
ryocyte foreign to essential self molecules. AMA
e, therefore, deﬁned as natural autoantibodies of
yreactive nature. An important feature of natural
odies is that they contribute to maintenance of
ne homeostasis and exert many functions such as
nce of apoptotic cells or selection of immune rep-
e [5]. Thus, the exposure of a mitochondrial anti-
uch as PDC-E2 in PBC is rather supposed to
te ﬁrst at early stages an innate and not an adaptive
ne response.
get better insight into the AMA-related pathogen-
f PBC one can look at the two co-occurring dis-
eases, Sjo¨gren’s syndrome and scleroderma that
express both diagnostic and functional active anti-recep-
tor antibodies. In patients with scleroderma diﬀerent
types of organ speciﬁc antibodies are associated with
diﬀerent clinical manifestations such as oesophageal
and gastrointestinal dysmotility and tissue ﬁbrosis
[6,7]. Furthermore, there is convincing evidence that
the glandular hypofunction in Sjo¨gren’s syndrome is
attributed to the antagonistic action of antibodies to
the muscarinic acetylcholine receptor M 3 [8].
Since proliferating bile ducts acquire all phenotypes
of neuroendocrine cells [9] it seems very likely that cho-
langiocyte-speciﬁc anti-receptor antibodies are also
induced in patients with PBC. Indeed, one even might
deﬁne PBC as a neuroendocrine autoimmune disease.
The concept of the maintenance function of innate
immune system would be also applicable to the diﬀerent
courses of PBC. This means that under normal non
pathological conditions, the immune system supports
the structural and functional integrity of cholangiocytes.
In contrast, overactivation of the self speciﬁc immune
activities would underlie the loss of bile duct mainte-
nance leading to the eruption of autoimmune disease.
Reﬂecting this kind of surveillance function asymptom-
atic, symptomatic and progressive courses become easily
understandable.
Macroautophagy induction has to be also considered
as a pathway in innate and adaptive immunity [10] since
apoptotic stimuli target mitochondria for degradation
by autophagy. Danger signals may also activate the cas-
pase cascade via the pro- and anti-apoptotic Bcl-2 fam-
ily [11]. Certainly, the question about the nature of the
so called danger signals cannot be answered. Following
Plotz’s view [12] one could argue that the xenobiotic
modiﬁed PDC-E2 antigen is especially chemoattractive
for immature dendritic cells and will be readily exposed
to cells of the innate and adaptive immune system. The
process of apoptosis inﬂuences the presentation of the
diﬀerent intracellular antigens. Integrity of cholangio-
cytes may, therefore, depend upon the balance of
ess under CC BY-NC-ND license.
protective (proliferative) and destructive (apoptotic)
mechanisms. Thus, natural occurring autoantibodies
may stimulate or inhibit apoptosis by interfering with
Bcl-2 proteins or with the large family of transmem-
brane receptors. This theoretical concept is convincingly
backed up by recent ﬁndings that UDCA can prevent
apoptosis by reducing the apoptotic threshold through
modulation of the classical mitochondrial pathway [13].
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What is the actual role of diagnosis and how to assess it?
To the Editor:
We read with interest the paper byMehta et al. [1] that
reported that due to imperfection of liver biopsy as a ref-
erence standard it is not possible to estimate the accuracy
of a non-invasive test for the diagnosis of liver ﬁbrosis.
However, we would like to challenge some points raised.
Diagnosis cannot be regarded as a primary outcome
but alternatively can be represented as a decisional node.
The identiﬁcation and staging of a disease (diagnosis)
should support the decision to treat a patient or not. The
utility of diagnosis derives from the beneﬁts of this deci-
sion. Thus, in the context of liver disease, patients with
severe ﬁbrosis have a worse prognosis and those with
signiﬁcant ﬁbrosis fare better with treatment. The iden-
tiﬁcation of these subgroups is useful and allows the def-
inition of their prognosis and initiation of eﬀective
treatment, but these diﬀerences in prognosis and beneﬁts
of treatment have widely been evaluated using exclu-
sively histological deﬁnition, even if imperfect. Actually,
no diagnostic test can be regarded as perfect and thus
there are no longer ‘‘gold” but only reference standards.
The limitations of liver biopsy are well known; the most
important being the high percentage of false-negative
results yielded in the cases of signiﬁcant or severe
ﬁbrosis.
In the study by Mehta et al. there is an implicit
assumption that the prognosis and the response to treat-
ment in patients with false-negative results at histology
are actually the same as in those with true-positive
results. This assumption has still to be unequivocally
proved. So far, it has not been possible to assume that
non-invasive ﬁbromarkers are more useful only for the
merit of reducing the false- negative rate of histology.
In fact, only the assessment of the prognosis of patients
with discrepant results (between histology and ﬁbromar-
kers) could deﬁne their actual advantage.
An unequivocal demonstration would entail a ran-
domized controlled trial comparing hard clinical out-
comes in patients in which the diagnosis of signiﬁcant
or severe ﬁbrosis was obtained either by histology or
by non-invasive ﬁbromarkers.
Furthermore, the analysis by Mehta et al. is limited to
the overall accuracy and AUC assessment: these are two
diagnostic measures of true results, but no information
can be derived on false-positive or -negative results.
However, the clinical utility of a diagnostic test depends
on false-negative and positive rate (i.e. on sensitivity and
speciﬁcity).
Finally, Mehta et al. [1] seem to conceive possible
alternatives to liver biopsy only in the form of a sin-
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